Navigation Links
Advanced Life Sciences Announces Successful Preclinical Data Supporting Restanza Intravenous Formulation for Hospital Use
Date:7/8/2010

CA-MRSA and pathogens associated with respiratory tract infections that are resistant to penicillins, macrolides, and fluoroquinolones. Restanza's demonstrated potency and ability to overcome bacterial resistance may be due to its mechanism of action resulting in specificity for its bacterial target. In addition to its utility in CABP, Restanza is also being investigated for the prophylactic treatment of inhalation anthrax post-exposure and other high priority biodefense pathogens, including plague and tularemia. The FDA has designated Restanza as an orphan drug for the prophylactic treatment of inhalation anthrax post exposure, as well as for use in treating plague and tularemia, but the drug is not yet approved for these or any other indications.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, Restanza, is a novel oral once-a-day antibiotic in late-stage development for the treatment of respiratory tract infections including CABP and biodefense pathogens including anthrax, plague and tularemia. For more information, please visit us on the web at www.advancedlifesciences.com or follow us on twitter at http://twitter.com/advancedlifesci.

Forward-Looking Statements

Any state
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million
2. Advanced Life Sciences Announces Second Quarter 2008 Financial Results
3. LUMEDX Introduces Advanced Multi-Modality, Multi-Vendor, Web-Enabled ECG Management Solution
4. Waters Brings Advanced Laboratory Data Management to Microsofts BioIT Alliance
5. Orange Coast Urology Offers Advanced In-Office Patient EVOLVE(R) Laser Prostate Treatment
6. Advanced Pest Control Earns Quality Pro Designation for General Pest Control Services
7. Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced Melanoma
8. Advanced Chemical Transport Opens Merced Facility
9. Advanced Life Sciences to Host Conference Call to Update Investors on Progress of Corporate Initiatives on October 1, 2008
10. Advanced Instruments Acquires D & F Control Systems Inc.
11. DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/8nqqdw/global_breast ) ... Breast Cancer Monoclonal Antibodies Market Outlook 2020" ... seems to dominate the breast cancer monoclonal antibody ... molecule, Herceptin has been able to dominate this ... breast cancer cells become recalcitrant and relapsed condition ...
(Date:5/27/2015)... AVIV, Israel , May 27, 2015  Tikcro ... first quarter ended March 31, 2015. ... the quarter, we continued pre-clinical work to generate functional ... in an early stage, we are encouraged by the ... this field as new antibodies which modulate immune checkpoints ...
(Date:5/27/2015)... May 27, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... personalized immune therapies for cancer, announced today that Dr. ... the Company, will be making an Industry Expert Theater ... Chicago on Saturday, May 30, 2015, ... Expert Theater in McCormick Place. Dr. Bosch ...
(Date:5/27/2015)... May 27, 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering and developing innovative therapies primarily in the ... on the status of the Company,s Series A ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... 21 shares of Series A Preferred Stock and ...
Breaking Biology Technology:Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3
... Ampio Pharmaceuticals, Inc. (OTC Bulletin Board: ... press release on July 27 , and provides the corrected ... the press release, Ampio has completed the final negotiations with DMI ... file a Form 8-K with the SEC announcing the definitive agreement ...
... AVANIR Pharmaceuticals, Inc. (Nasdaq: ... Annual Canaccord Genuity Growth Conference on Tuesday, August 10th at ... at the InterContinental Hotel in Boston .  The Canaccord Genuity Growth ... and industry leaders.   , , ...
... PLYMOUTH MEETING, Pa. , Aug. 2 /PRNewswire-Asia-FirstCall/ -- BMP ... today announced,that the Company plans to release second quarter 2010 financial results on, ... , , ... a conference call at 5:00 pm ET on August 9, ...
Cached Biology Technology:CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc. 2AVANIR to Present at the Canaccord Genuity Growth Conference 2BMP Sunstone to Report Second Quarter 2010 Financial Results 2
(Date:5/14/2015)... and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has announced ... Smart Mobile Devices " report to their offering. ... watershed year for fingerprint sensors in smartphones and tablets, ... fingerprint sensors a raison d,etre in the mobile milieu ... must-have feature in flagship smartphones. The key ...
(Date:5/11/2015)... 2015  Synaptics Incorporated (NASDAQ: SYNA ), ... announced the appointment of Wajid Ali ... reporting to Rick Bergman , President and ... Officer, Kathleen Bayless , who announced her ... Ali brings extensive financial management expertise to Synaptics, ...
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... (Nov. 3, 2010) -- Scientists at Weill Cornell Medical College ... prostate cancer by uncovering evidence that it is not one ... be measured and, in the future, destroyed by targeted therapy., ... by of Dr. Mark A. Rubin, the Homer T. Hirst ...
... Salk Institute for Biological Studies and Columbia University Medical ... The Leona M. and Harry B. Helmsley Charitable Trust, ... induced pluripotent stem (iPS) cells to gain new insight ... "Stem cell research is of immense importance to ...
... plants can be predicted based on chromosome imbalances, a ... or deletion of genes and the organization of the ... Purdue University researcher. The findings identify easily measured ... Brian Dilkes, a Purdue assistant professor of horticulture. Understanding ...
Cached Biology News:Prostate cancer's multiple personalities revealed 2Helmsley Charitable Trust awards more than $15 million to Salk Institute-CUMC 2Helmsley Charitable Trust awards more than $15 million to Salk Institute-CUMC 3Chromosome imbalances lead to predictable plant defects 2